Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IN-1130
- Development stage
- Preclinical
- Lead developer
- SK Chemicals
- Modality
- Small Molecules
01
Overview
IN-1130: sourced facts only. name: "IN-1130, a novel small molecule ALK5 inhibitor" [1] target: "IN-1130, a novel small molecule ALK5 inhibitor, inhibited the purified kinase domain of ALK5-mediated Smad3 phosphorylation with an IC(50) value of 5.3 nM." [1] developer: "R&D Center, In2Gen Co., Ltd, Samsung Cancer Research Institute, Seoul National University College of Medicine, Chongno-gu, Seoul, Republic of Korea." [1] stage: "We evaluated the efficacy of IN-1130 to block renal fibrogenesis induced by unilateral ureteral obstruction (UUO) in rats." [1] modality: "IN-1130, a novel small molecule ALK5 inhibitor" [1]
02
Targets
TGFBR1
Beyond the preview
Go deeper on IN-1130.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IN-1130.